Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Landiolol - AOP Orphan Pharmaceuticals

Next Previous
X
Search
Drug Profile

Landiolol - AOP Orphan Pharmaceuticals

Alternative Names: AOP200704; LDLL600; Onoact; Rapibloc

Latest Information Update: 23 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AOP Orphan Pharmaceuticals AG
  • Developer AOP Orphan Pharmaceuticals AG; Eagle Pharmaceuticals
  • Class Antiarrhythmics; Morpholines; Small molecules; Urea compounds
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Tachycardia
  • Preregistration Supraventricular tachycardia
  • Phase III Atrial fibrillation

Most Recent Events

  • 22 Jan 2024 Phase-III clinical trials in Atrial fibrillation in USA, Canada and European Union (IV) prior to January 2024 (AOP Orphan Pharmaceuticals AG pipeline, January 2024)
  • 30 Nov 2023 Registered for Tachycardia in Canada (IV)
  • 12 Sep 2022 Launched for Tachycardia in European Union (IV) (AOP Orphan Pharmaceuticals AG pipeline, September 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top